Cencora, Inc. (NYSE:COR) Shares Purchased by Ritholtz Wealth Management

Ritholtz Wealth Management lifted its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 8.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,212 shares of the company's stock after purchasing an additional 979 shares during the period. Ritholtz Wealth Management's holdings in Cencora were worth $3,396,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of COR. Avestar Capital LLC purchased a new stake in shares of Cencora in the fourth quarter valued at approximately $208,000. Vontobel Holding Ltd. grew its stake in Cencora by 46.9% in the 4th quarter. Vontobel Holding Ltd. now owns 6,245 shares of the company's stock valued at $1,403,000 after acquiring an additional 1,995 shares during the period. New Mexico Educational Retirement Board increased its holdings in Cencora by 2.5% in the 4th quarter. New Mexico Educational Retirement Board now owns 8,291 shares of the company's stock worth $1,863,000 after acquiring an additional 200 shares in the last quarter. WASHINGTON TRUST Co increased its holdings in Cencora by 37.7% in the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock worth $38,000 after acquiring an additional 46 shares in the last quarter. Finally, Everhart Financial Group Inc. raised its position in Cencora by 2.0% during the fourth quarter. Everhart Financial Group Inc. now owns 3,076 shares of the company's stock worth $691,000 after acquiring an additional 61 shares during the period. Institutional investors and hedge funds own 97.52% of the company's stock.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Bank of America lifted their target price on shares of Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research report on Friday, April 11th. Robert W. Baird lifted their price objective on Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Citigroup boosted their price objective on Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. Wells Fargo & Company upgraded Cencora from an "equal weight" rating to an "overweight" rating and raised their target price for the company from $274.00 to $337.00 in a research report on Tuesday, June 3rd. Finally, Morgan Stanley set a $288.00 price target on Cencora in a research note on Tuesday, April 15th. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $306.91.

Cencora Stock Performance

NYSE COR opened at $295.12 on Monday. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The stock's fifty day moving average is $287.24 and its two-hundred day moving average is $261.82. The firm has a market capitalization of $57.20 billion, a P/E ratio of 41.98, a price-to-earnings-growth ratio of 1.31 and a beta of 0.58. Cencora, Inc. has a fifty-two week low of $218.65 and a fifty-two week high of $309.35.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, beating the consensus estimate of $4.07 by $0.35. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The firm had revenue of $75.50 billion for the quarter, compared to analysts' expectations of $75.41 billion. During the same quarter in the previous year, the company posted $3.80 EPS. The company's revenue was up 10.3% compared to the same quarter last year. On average, research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Stockholders of record on Friday, May 16th were given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.75%. The ex-dividend date of this dividend was Friday, May 16th. Cencora's payout ratio is presently 25.52%.

Insider Activity at Cencora

In related news, EVP Elizabeth S. Campbell sold 4,127 shares of the firm's stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $268.28, for a total transaction of $1,107,191.56. Following the completion of the sale, the executive vice president now directly owns 14,665 shares of the company's stock, valued at approximately $3,934,326.20. This trade represents a 21.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Robert P. Mauch sold 4,969 shares of the stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the transaction, the chief executive officer now directly owns 47,582 shares of the company's stock, valued at approximately $13,766,900.06. This trade represents a 9.46% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 38,253 shares of company stock worth $10,582,297. Insiders own 10.80% of the company's stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.